Literature DB >> 15366975

The general practice research database: role in pharmacovigilance.

Louise Wood1, Carlos Martinez.   

Abstract

The General Practice Research Database (GPRD) is the world's largest computerised database of anonymised longitudinal clinical records from primary care. The database already has an international reputation in the field of drug safety signal evaluation where the results of GPRD-based pharmacoepidemiological studies have been used to inform regulatory pharmacovigilance decision making. The characteristics and richness of the data are such that the GPRD is likely to prove a key data resource for the proactive pharmacovigilance anticipated in risk management and pharmacovigilance plans. An update of recent developments to the database and new data available from it -- including spontaneously recorded suspected adverse drug reactions -- is presented in the article, with a description of how the data can be used to support a variety of pharmacovigilance applications. The possibility of using the GPRD in signal detection and assessment of the impact of pharmacovigilance activities in the future is also discussed.

Mesh:

Year:  2004        PMID: 15366975     DOI: 10.2165/00002018-200427120-00004

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  35 in total

Review 1.  Quantitative methods in pharmacovigilance: focus on signal detection.

Authors:  Manfred Hauben; Xiaofeng Zhou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

2.  Pharmaceutical risk management: a call to arms for pharmacoepidemiology.

Authors:  David L Hyslop; Holly A Read; Daniel N Masica; James G Kotsanos
Journal:  Pharmacoepidemiol Drug Saf       Date:  2002 Jul-Aug       Impact factor: 2.890

3.  The role of pharmacoepidemiology in pharmacovigilance: a conference at the 6th ESOP Meeting, Budapest, 28 September 1998.

Authors:  L Abenhaim; N Moore; B Bégaud
Journal:  Pharmacoepidemiol Drug Saf       Date:  1999-04       Impact factor: 2.890

4.  The status of pharmacoepidemiology in a regulatory environment.

Authors:  C I Neutel
Journal:  Pharmacoepidemiol Drug Saf       Date:  2000-01       Impact factor: 2.890

5.  A Bayesian neural network method for adverse drug reaction signal generation.

Authors:  A Bate; M Lindquist; I R Edwards; S Olsson; R Orre; A Lansner; R M De Freitas
Journal:  Eur J Clin Pharmacol       Date:  1998-06       Impact factor: 2.953

6.  Use of the UK General Practice Research Database for pharmacoepidemiology.

Authors:  L A García Rodríguez; S Pérez Gutthann
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

7.  Adverse drug reactions: finding the needle in the haystack.

Authors:  I R Edwards
Journal:  BMJ       Date:  1997-08-30

8.  Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs.

Authors:  L A García Rodríguez; H Jick
Journal:  Lancet       Date:  1994-03-26       Impact factor: 79.321

9.  Anticonvulsants and congenital malformations.

Authors:  S S Jick; B Z Terris
Journal:  Pharmacotherapy       Date:  1997 May-Jun       Impact factor: 4.705

10.  Treatment patterns among newly diagnosed heart failure patients in general practice.

Authors:  Saga Johansson; Mari-Ann Wallander; Ana Ruigómez; RodríguezLuisAlberto García
Journal:  Eur J Clin Pharmacol       Date:  2002-01       Impact factor: 2.953

View more
  53 in total

1.  Mortality in children and adolescents prescribed antipsychotic medication: a retrospective cohort study using the UK general practice research database.

Authors:  Fariz A Rani; Patrick Byrne; Noel Cranswick; Macey L Murray; Ian C K Wong
Journal:  Drug Saf       Date:  2011-09-01       Impact factor: 5.606

2.  Prioritizing children's medicines for research: a pharmaco-epidemiological study of antiepileptic drugs.

Authors:  Ruth Ackers; Macey L Murray; Frank M C Besag; Ian C K Wong
Journal:  Br J Clin Pharmacol       Date:  2007-01-25       Impact factor: 4.335

3.  Active computerized pharmacovigilance using natural language processing, statistics, and electronic health records: a feasibility study.

Authors:  Xiaoyan Wang; George Hripcsak; Marianthi Markatou; Carol Friedman
Journal:  J Am Med Inform Assoc       Date:  2009-03-04       Impact factor: 4.497

4.  Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study.

Authors:  Carlos Martinez; Stephan Rietbrock; Lesley Wise; Deborah Ashby; Jonathan Chick; Jane Moseley; Stephen Evans; David Gunnell
Journal:  BMJ       Date:  2005-02-19

5.  Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK.

Authors:  Claudia Becker; Susan S Jick; Christoph R Meier
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

6.  Risk of stroke in people with type 2 diabetes in the UK: a study using the General Practice Research Database.

Authors:  H E Mulnier; H E Seaman; V S Raleigh; S S Soedamah-Muthu; H M Colhoun; R A Lawrenson; C S De Vries
Journal:  Diabetologia       Date:  2006-10-27       Impact factor: 10.122

7.  Proton Pump Inhibitor Use and Risk of Developing Alzheimer's Disease or Vascular Dementia: A Case-Control Analysis.

Authors:  Patrick Imfeld; Michael Bodmer; Susan S Jick; Christoph R Meier
Journal:  Drug Saf       Date:  2018-12       Impact factor: 5.606

8.  Long-term metformin use is associated with decreased risk of breast cancer.

Authors:  Michael Bodmer; Christian Meier; Stephan Krähenbühl; Susan S Jick; Christoph R Meier
Journal:  Diabetes Care       Date:  2010-03-18       Impact factor: 19.112

9.  Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: a nested case-control study.

Authors:  Carlos Martinez; Themistocles L Assimes; Daniel Mines; Sophie Dell'aniello; Samy Suissa
Journal:  BMJ       Date:  2010-02-05

10.  Association of smoking with amyotrophic lateral sclerosis risk and survival in men and women: a prospective study.

Authors:  Alvaro Alonso; Giancarlo Logroscino; Susan S Jick; Miguel A Hernán
Journal:  BMC Neurol       Date:  2010-01-14       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.